

We claim:

1. A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.
2. An inhaler according to Claim 1 containing said drug formulation.
3. An inhaler according to Claim 2, wherein said drug formulation further comprises a surfactant.
4. An inhaler according to Claim 2 or Claim 3, wherein said drug formulation further comprises a polar cosolvent.
5. An inhaler according to Claim 2 wherein said drug formulation further comprises 0.01 to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant.
6. An inhaler according to any one of Claims 2 to 5, wherein said drug formulation comprises fluticasone propionate or a physiologically acceptable solvate thereof in combination with a bronchodilator or an antiallergic.

7. An inhaler according to Claim 6, wherein said drug formulation comprises fluticasone propionate in combination with salmeterol xinafoate.

8. An inhaler according to Claim 2, wherein said drug formulation consists essentially of fluticasone propionate or a physiologically acceptable solvate thereof, optionally in combination with one or more other pharmacologically  
5 active agents, and a fluorocarbon propellant.

9. An inhaler according to Claim 8, wherein said drug formulation consists essentially of fluticasone propionate or a physiologically acceptable solvate thereof in combination with a bronchodilator or an antiallergic.

10. An inhaler according to Claim 9, wherein said drug formulation consists essentially of fluticasone propionate or a physiologically acceptable solvate thereof in combination with salmeterol or a physiologically acceptable  
5 salt thereof.

11. An inhaler according to Claim 10, wherein said drug formulation consists essentially of fluticasone propionate in combination with salmeterol xinafoate.

12. An inhaler according to Claim 2, wherein said drug formulation consists of fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant.

13. An inhaler according to any one of Claims 2 to 12, wherein the fluorocarbon propellant is 1,1,1,2-

tetrafluoroethane, or 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof.

14. An inhaler according to Claim 13, wherein the fluorocarbon propellant is 1,1,1,2-tetrafluoroethane.

15. An inhaler according to any one of Claims 1 to 14 comprising a can made of metal wherein part or all of the internal metallic surfaces are coated.

16. An inhaler according to Claim 15 wherein the metal is aluminium or an alloy thereof.

17. An inhaler according to any one of Claims 1 to 16 wherein said fluorocarbon polymer is a perfluorocarbon polymer.

18. An inhaler according to Claim 17 wherein said fluorocarbon polymer is selected from PTFE, PFA, FEP and mixtures thereof.

19. An inhaler according to any one of Claims 1 to 18, wherein said fluorocarbon polymer is in combination with a non-fluorocarbon polymer selected from polyamideimide and polyethersulphone.

20. An inhaler according to any one of Claims 1 to 19 comprising a substantially ellipsoidal base.

21. A metered dose inhaler system comprising a metered dose inhaler according to any one of Claim 1 to 20 fitted

into suitable channeling device for oral or nasal inhalation of the drug formulation.

22. Use of a metered dose inhaler system according to Claim 21 for the treatment of respiratory disorders.